Cargando…
Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
OBJECTIVES: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine. METHODS: We performed a cross-over study in which HIV-infected...
Autores principales: | , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465101/ https://www.ncbi.nlm.nih.gov/pubmed/22687893 http://dx.doi.org/10.1093/jac/dks207 |
_version_ | 1782245506217410560 |
---|---|
author | Byakika-Kibwika, Pauline Lamorde, Mohammed Mayito, Jonathan Nabukeera, Lillian Namakula, Rhoda Mayanja-Kizza, Harriet Katabira, Elly Ntale, Muhammad Pakker, Nadine Ryan, Mairin Hanpithakpong, Warunee Tarning, Joel Lindegardh, Niklas de Vries, Peter J. Khoo, Saye Back, David Merry, Concepta |
author_facet | Byakika-Kibwika, Pauline Lamorde, Mohammed Mayito, Jonathan Nabukeera, Lillian Namakula, Rhoda Mayanja-Kizza, Harriet Katabira, Elly Ntale, Muhammad Pakker, Nadine Ryan, Mairin Hanpithakpong, Warunee Tarning, Joel Lindegardh, Niklas de Vries, Peter J. Khoo, Saye Back, David Merry, Concepta |
author_sort | Byakika-Kibwika, Pauline |
collection | PubMed |
description | OBJECTIVES: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine. METHODS: We performed a cross-over study in which HIV-infected adults received standard six-dose artemether/lumefantrine 80/480 mg before and at efavirenz or nevirapine steady state. Artemether, dihydroartemisinin, lumefantrine, efavirenz and nevirapine plasma concentrations were measured and compared. RESULTS: Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01). Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01). Lumefantrine C(max) and AUC were non-significantly reduced by nevirapine. Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure. CONCLUSIONS: Co-administration of artemether/lumefantrine with efavirenz or nevirapine resulted in a reduction in artemether, dihydroartemisinin, lumefantrine and nevirapine exposure. These drug interactions may increase the risk of malaria treatment failure and development of resistance to artemether/lumefantrine and nevirapine. Clinical data from population pharmacokinetic and pharmacodynamic trials evaluating the impact of these drug interactions are urgently needed. |
format | Online Article Text |
id | pubmed-3465101 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2012 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-34651012012-10-07 Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults Byakika-Kibwika, Pauline Lamorde, Mohammed Mayito, Jonathan Nabukeera, Lillian Namakula, Rhoda Mayanja-Kizza, Harriet Katabira, Elly Ntale, Muhammad Pakker, Nadine Ryan, Mairin Hanpithakpong, Warunee Tarning, Joel Lindegardh, Niklas de Vries, Peter J. Khoo, Saye Back, David Merry, Concepta J Antimicrob Chemother Original Research OBJECTIVES: Co-administration of artemether/lumefantrine with antiretroviral therapy has potential for pharmacokinetic drug interactions. We investigated drug–drug interactions between artemether/lumefantrine and efavirenz or nevirapine. METHODS: We performed a cross-over study in which HIV-infected adults received standard six-dose artemether/lumefantrine 80/480 mg before and at efavirenz or nevirapine steady state. Artemether, dihydroartemisinin, lumefantrine, efavirenz and nevirapine plasma concentrations were measured and compared. RESULTS: Efavirenz significantly reduced artemether maximum concentration (C(max)) and plasma AUC (median 29 versus 12 ng/mL, P < 0.01, and 119 versus 25 ng · h/mL, P < 0.01), dihydroartemisinin C(max) and AUC (median 120 versus 26 ng/mL, P < 0.01, and 341 versus 84 ng · h/mL, P < 0.01), and lumefantrine C(max) and AUC (median 8737 versus 6331 ng/mL, P = 0.03, and 280 370 versus 124 381 ng · h/mL, P < 0.01). Nevirapine significantly reduced artemether C(max) and AUC (median 28 versus 11 ng/mL, P < 0.01, and 123 versus 34 ng · h/mL, P < 0.01) and dihydroartemisinin C(max) and AUC (median 107 versus 59 ng/mL, P < 0.01, and 364 versus 228 ng · h/mL, P < 0.01). Lumefantrine C(max) and AUC were non-significantly reduced by nevirapine. Artemether/lumefantrine reduced nevirapine C(max) and AUC (median 8620 versus 4958 ng/mL, P < 0.01, and 66 329 versus 35 728 ng · h/mL, P < 0.01), but did not affect efavirenz exposure. CONCLUSIONS: Co-administration of artemether/lumefantrine with efavirenz or nevirapine resulted in a reduction in artemether, dihydroartemisinin, lumefantrine and nevirapine exposure. These drug interactions may increase the risk of malaria treatment failure and development of resistance to artemether/lumefantrine and nevirapine. Clinical data from population pharmacokinetic and pharmacodynamic trials evaluating the impact of these drug interactions are urgently needed. Oxford University Press 2012-09 2012-06-11 /pmc/articles/PMC3465101/ /pubmed/22687893 http://dx.doi.org/10.1093/jac/dks207 Text en © The Author 2012. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Research Byakika-Kibwika, Pauline Lamorde, Mohammed Mayito, Jonathan Nabukeera, Lillian Namakula, Rhoda Mayanja-Kizza, Harriet Katabira, Elly Ntale, Muhammad Pakker, Nadine Ryan, Mairin Hanpithakpong, Warunee Tarning, Joel Lindegardh, Niklas de Vries, Peter J. Khoo, Saye Back, David Merry, Concepta Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults |
title | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults |
title_full | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults |
title_fullStr | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults |
title_full_unstemmed | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults |
title_short | Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults |
title_sort | significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in hiv-infected ugandan adults |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3465101/ https://www.ncbi.nlm.nih.gov/pubmed/22687893 http://dx.doi.org/10.1093/jac/dks207 |
work_keys_str_mv | AT byakikakibwikapauline significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT lamordemohammed significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT mayitojonathan significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT nabukeeralillian significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT namakularhoda significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT mayanjakizzaharriet significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT katabiraelly significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT ntalemuhammad significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT pakkernadine significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT ryanmairin significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT hanpithakpongwarunee significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT tarningjoel significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT lindegardhniklas significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT devriespeterj significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT khoosaye significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT backdavid significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults AT merryconcepta significantpharmacokineticinteractionsbetweenartemetherlumefantrineandefavirenzornevirapineinhivinfectedugandanadults |